Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
- PMID: 24975812
- PMCID: PMC4252359
- DOI: 10.1016/j.vaccine.2014.06.065
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
Abstract
Synthetic oligonucleotides (ODN) that express unmethylated "CpG motifs" trigger cells that express Toll-like receptor 9. In humans this includes plasmacytoid dendritic cells and B cells. CpG ODN induce an innate immune response characterized by the production of Th1 and pro-inflammatory cytokines. Their utility as vaccine adjuvants was evaluated in a number of clinical trials. Results indicate that CpG ODN improve antigen presentation and the generation of vaccine-specific cellular and humoral responses. This work provides an up-to-date overview of the utility of CpG ODN as adjuvants for vaccines targeting infectious agents and cancer.
Keywords: Adjuvant; Cancer; CpG olignucleotide; Infection; Toll-like receptor.
Published by Elsevier Ltd.
Conflict of interest statement
Dr. Klinman and members of his lab have patents related to the use of CpG ODN. All rights to such patents have been assigned to the Federal Government.
Similar articles
-
Adjuvant properties of CpG oligonucleotides in primates.Methods Mol Med. 2006;127:139-58. doi: 10.1385/1-59745-168-1:139. Methods Mol Med. 2006. PMID: 16988453 Review.
-
CpG DNA as a vaccine adjuvant.Expert Rev Vaccines. 2011 Apr;10(4):499-511. doi: 10.1586/erv.10.174. Expert Rev Vaccines. 2011. PMID: 21506647 Free PMC article. Review.
-
CpG Oligonucleotides as Vaccine Adjuvants.Methods Mol Biol. 2021;2197:51-85. doi: 10.1007/978-1-0716-0872-2_4. Methods Mol Biol. 2021. PMID: 32827132 Review.
-
Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.Vaccine. 2010 Feb 23;28(8):1919-23. doi: 10.1016/j.vaccine.2009.10.094. Vaccine. 2010. PMID: 20188247 Free PMC article.
-
Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.Mol Pharm. 2017 Aug 7;14(8):2815-2823. doi: 10.1021/acs.molpharmaceut.7b00335. Epub 2017 Jul 24. Mol Pharm. 2017. PMID: 28686452
Cited by
-
Natural and Synthetic Saponins as Vaccine Adjuvants.Vaccines (Basel). 2021 Mar 5;9(3):222. doi: 10.3390/vaccines9030222. Vaccines (Basel). 2021. PMID: 33807582 Free PMC article. Review.
-
Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose.Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):E4133-42. doi: 10.1073/pnas.1600299113. Epub 2016 Jul 5. Proc Natl Acad Sci U S A. 2016. PMID: 27382155 Free PMC article.
-
Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity.Nat Cancer. 2022 Apr;3(4):437-452. doi: 10.1038/s43018-022-00352-7. Epub 2022 Apr 7. Nat Cancer. 2022. PMID: 35393580 Free PMC article.
-
Harnessing the Induction of CD8+ T-Cell Responses Through Metabolic Regulation by Pathogen-Recognition-Receptor Triggering in Antigen Presenting Cells.Front Immunol. 2018 Oct 25;9:2372. doi: 10.3389/fimmu.2018.02372. eCollection 2018. Front Immunol. 2018. PMID: 30410483 Free PMC article. Review.
-
Translating nucleic acid-sensing pathways into therapies.Nat Rev Immunol. 2015 Sep 15;15(9):529-44. doi: 10.1038/nri3875. Epub 2015 Aug 21. Nat Rev Immunol. 2015. PMID: 26292638 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical